[Adverse effects of chemical mediator release inhibitors].
Onoda
Masahito
M
Department of Allergy and Collagen Disease, Tokyo Metropolitan Komagome Hospital.
Inokuma
Shigeko
S
Ikezawa
Zenro
Z
D000280:Administration, Inhalation; D000284:Administration, Oral; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy; D000075202:Contraindications; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000009:adverse effects*; D003556:Cystitis / Q000139:chemically induced*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D004066:Digestive System Diseases / Q000139:chemically induced*; D003875:Drug Eruptions / Q000209:etiology; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D062367:ortho-Aminobenzoates / Q000008:administration & dosage / Q000009:adverse effects*
D018926:Anti-Allergic Agents; D062367:ortho-Aminobenzoates; C012293:tranilast; D004205:Cromolyn Sodium